The newly authorized administration process requires two 250-milligram injections given once weekly during the initiation phase. Following 18 months of initial intravenous or subcutaneous treatment, patients may transition to a maintenance dose of 360 milligrams per week. This shift aims to reduce the logistical burden on patients who previously relied on clinical settings for medication delivery.

Eisai maintains primary responsibility for global development and regulatory filings, while both companies continue to co-promote and co-commercialize the drug in the United States. By providing a subcutaneous option, the pharmaceutical partners seek to broaden access to therapy for adults categorized under the early Alzheimer’s diagnosis spectrum.